Arterium Company Highlights 2012
4
* According to the market research system «PharmXplorer», © «Prohima Research». № 1 In Ukrainian pharma companies Rx sales № 1 In antibacterial drugs (J) Being one of the leading Ukrainian pharmaceutical companies Arterium is striving to innovate the industry and to enhance human health and life. Specialized mostly in production of prescription medications we traditionally occupy leading positions in Ukraine. Our 2012 revenue forecast is above one billion UAH. № 1 In Hospital segment at the market 22 new products were launched in Ukraine: 5 new human drugs Neuroxon, Linezolidin, Gliteik, Glucose, Casark H 3 veterinary products: Cefinel, Ceftriaxone, Cefazoline 14 new dosages and delivery forms Neuroxon became the best new product launch of the year*. Due to our rising presence in CV treatments we provided general sponsorship for the XIII Congress of Cardiologists in Ukraine. Company Highlights 2012
Transcript of Arterium Company Highlights 2012
* According to the market research system «PharmXplorer», © «Prohima Research».
№ 1 In Ukrainian
pharmacompaniesRx sales
№ 1 In
antibacterialdrugs (J)
Being one of the leading Ukrainian pharmaceutical companies Arterium is striving to innovate the industry and
to enhance human health and life.
Specialized mostly in production of prescriptionmedications we traditionally occupyleading positions in Ukraine.Our 2012 revenue forecastis above one billion UAH.
№ 1In Hospitalsegment atthe market
22 new products were launched in Ukraine:5 new human drugs Neuroxon, Linezolidin,
Gliteik, Glucose, Casark H3 veterinary products: Cefinel, Ceftriaxone, Cefazoline
14 new dosages and delivery forms
Neuroxon became the best newproduct launch of the year*.Due to our rising presence in CV treatmentswe provided general sponsorship for theXIII Congress of Cardiologists in Ukraine.
Company Highlights 2012
We strengthened our position in Russia,Belarus, Kazakhstan, Uzbekistan andstarted operations in Vietnam.
27 new registrations obtainedat export markets.
Persistently developing our R&D expertisewe completed 3 clinical trials, 8 preclinical
trials and 4 trials for veterinary drugs.
We gave a significant emphasis to improvementof our original products as well as support
to scientific research activity.
Arterium joinedAssociation of Clinical Trials
Organization in Russia.
Company Highlights 2012
We opened next new productionfacility for parental solutionsat «Galychpharm», Lviv.
New GMP certificate receivedfor β-lactam solid forms production
site at «Kievmedpreparat», Kyiv.
With our profound experienceand strong position in implementation
of ERP solutions we extended IFS Applicationsystem to the operations of «Galychpharm».
Company Highlights 2012
* According to the report of the Center of CSR Development.
Arterium joined the Center of CorporateSocial Responsibility Development.
We achieved a leadingposition in Transparency
Index among pharmaceuticalcompanies operating in Ukraine*.
We believe that our CSR project«Routes of Health» is a good contributioninto promotion of healthy lifestyleamong Ukrainian people.
Play the video
Company Highlights 2012
